

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

PE/Dazzle(TM) 594 anti-mouse CD39

RRID:AB_2750322

Type: Antibody

Proper Citation

BioLegend Cat# 143812, RRID:AB_2750322

Antibody Information

URL: http://antibodyregistry.org/AB_2750322

Proper Citation: BioLegend Cat# 143812, RRID:AB_2750322

Target Antigen: CD39

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Dazzle(TM) 594 anti-mouse CD39

Description: This monoclonal targets CD39

Target Organism: mouse

Clone ID: Clone Duha59

Antibody ID: AB_2750322

Vendor: BioLegend

Catalog Number: 143812

Alternative Catalog Numbers: 143811

Record Creation Time: 20250819T232406+0000

Record Last Update: 20250820T051351+0000

Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-mouse CD39.

No alerts have been found for PE/Dazzle(TM) 594 anti-mouse CD39.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. *Immunity*, 58(8), 1966.

Pereira P, et al. (2025) Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. *Cell reports*, 44(3), 115388.

Baharom F, et al. (2022) Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. *Cell*, 185(23), 4317.

Bhattacharjee A, et al. (2021) Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy. *Immunity*, 54(8), 1745.

Dammeijer F, et al. (2020) The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. *Cancer cell*, 38(5), 685.